220 related articles for article (PubMed ID: 11153678)
21. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral therapy. Sequencing antiretrovirals.
MacArthur RD
AIDS Read; 2000 Jun; 10(6):359-64. PubMed ID: 10881367
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
[TBL] [Abstract][Full Text] [Related]
24. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization.
Kagan RM; Merigan TC; Winters MA; Heseltine PN
Antivir Ther; 2004 Oct; 9(5):827-8. PubMed ID: 15535422
[No Abstract] [Full Text] [Related]
25. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
[TBL] [Abstract][Full Text] [Related]
26. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.
Shafer RW; Warford A; Winters MA; Gonzales MJ
J Virol Methods; 2000 May; 86(2):143-53. PubMed ID: 10785289
[TBL] [Abstract][Full Text] [Related]
27. Resistance against reverse transcriptase inhibitors.
O'Brien WA
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S185-92. PubMed ID: 10860904
[TBL] [Abstract][Full Text] [Related]
28. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
29. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
[No Abstract] [Full Text] [Related]
30. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1.
Heredia A; Margolis D; Oldach D; Hazen R; Le N; Redfield R
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):406-7. PubMed ID: 10634204
[No Abstract] [Full Text] [Related]
31. A fossil record of zidovudine resistance in transmitted isolates of HIV-1.
Kuritzkes DR
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13485-7. PubMed ID: 11717419
[No Abstract] [Full Text] [Related]
32. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of drug resistance mutations in Spain among both naive and pretreated patients.
Soriano V
Antivir Ther; 1999; 4 Suppl 3():57-63. PubMed ID: 16021872
[TBL] [Abstract][Full Text] [Related]
34. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
35. Reverse transcriptase fidelity and HIV-1 variation.
Preston BD
Science; 1997 Jan; 275(5297):228-9; author reply 230-1. PubMed ID: 8999549
[No Abstract] [Full Text] [Related]
36. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Clevenbergh P; Durant J; Halfon P; del Giudice P; Mondain V; Montagne N; Schapiro JM; Boucher CA; Dellamonica P
Antivir Ther; 2000 Mar; 5(1):65-70. PubMed ID: 10846595
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V
AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196
[TBL] [Abstract][Full Text] [Related]
38. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
[TBL] [Abstract][Full Text] [Related]
39. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
Hecht FM; Grant RM; Petropoulos CJ; Dillon B; Chesney MA; Tian H; Hellmann NS; Bandrapalli NI; Digilio L; Branson B; Kahn JO
N Engl J Med; 1998 Jul; 339(5):307-11. PubMed ID: 9682043
[No Abstract] [Full Text] [Related]
40. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
Balzarini J
Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
